Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

内科学 肾功能 肾 肌酐 终末期肾病 糖尿病 急性肾损伤 泌尿系统 糖尿病肾病
作者
Glenn M Chertow,Priya Vart,Niels Jongs,Robert D. Toto,José Luis Górriz,Fan Fan Hou,John J.V. McMurray,Ricardo Correa‐Rotter,PETER ROSSING,C David Sjöström,Bergur V Stefansson,Anna Maria Langkilde,David C. Wheeler,Hiddo J L Heerspink,DAPA-CKD Trial Committees and Investigators
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:32 (9): 2352-2361 被引量:178
标识
DOI:10.1681/asn.2021020167
摘要

Significance Statement Relatively little is known about the relative safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with advanced (stage 4) CKD. The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial enrolled patients with CKD with or without type 2 diabetes (mean eGFR 43 ± 12 ml/min per 1.73m 2 ), finding that patients receiving the drug had lower risks of major kidney and cardiovascular events and an attenuation of progressive eGFR loss compared with patients receiving placebo. In this analysis within a subgroup of patients with stage 4 CKD and albuminuria, the authors found that the benefits of the SGLT2 inhibitor dapagliflozin in patients with baseline eGFR<30 ml/min per 1.73m 2 were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks. Background In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in patients with CKD with or without type 2 diabetes. Methods Adults with eGFR of 25–75 ml/min per 1.73 m 2 and urinary albumin-to-creatinine ratio of 200–5000 mg/g had been randomized to receive dapagliflozin 10 mg/d or placebo. Here, we conducted a prespecified analysis of dapagliflozin’s effects in patients with stage 4 CKD (eGFR,30 ml/min per 1.73 m 2 ) at baseline. The primary end point was a composite of time to ≥50% sustained decline in eGFR, ESKD, or kidney or cardiovascular death. Secondary end points were a kidney composite (same as the primary end point but without cardiovascular death), a composite of cardiovascular death or heart failure hospitalization, and all-cause death. Results A total of 293 participants with stage 4 CKD received dapagliflozin and 331 received placebo. Patients with stage 4 CKD randomized to dapagliflozin experienced a 27% (95% confidence interval [95% CI]: −2 to 47%) reduction in the primary composite endpoint, and 29% (−2 to 51%), 17% (−53 to 55%), and 32% (−21 to 61%) reductions in the kidney, cardiovascular and mortality endpoints, respectively, relative to placebo. Interaction P-values were 0.22, 0.13, 0.63, and 0.95, respectively, comparing CKD stages 4 versus 2/3. The eGFR slope declined by 2.15 and 3.38 ml/min per 1.73 m 2 per year in the dapagliflozin and placebo groups, respectively ( P =0.005). Patients treated with dapagliflozin or placebo had similar rates of serious adverse events and adverse events of interest. Conclusions Among patients with stage 4 CKD and albuminuria, the effects of dapagliflozin were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘汉淼完成签到,获得积分0
1秒前
Frank完成签到 ,获得积分10
1秒前
墨痕完成签到,获得积分10
2秒前
3秒前
4秒前
Hhong完成签到,获得积分10
5秒前
avanti完成签到,获得积分10
6秒前
stella完成签到 ,获得积分10
6秒前
iggyxhjtl完成签到,获得积分10
7秒前
Orange的应助被茴香采纳,获得10
7秒前
Hello的应助被Zhang采纳,获得10
8秒前
小猪完成签到,获得积分10
8秒前
卿霜完成签到 ,获得积分10
9秒前
洽洽瓜子shine完成签到,获得积分10
9秒前
太阳女神完成签到,获得积分10
9秒前
wary关注了科研通微信公众号
10秒前
wwwy完成签到,获得积分10
11秒前
昏睡的坚果完成签到 ,获得积分10
11秒前
Rming完成签到,获得积分10
11秒前
ilucce完成签到,获得积分10
11秒前
pihriyyy完成签到,获得积分10
12秒前
meimei完成签到,获得积分10
13秒前
董ww完成签到 ,获得积分10
13秒前
13秒前
Dogged完成签到 ,获得积分10
14秒前
坚强的翠容完成签到,获得积分10
15秒前
向往的鱼完成签到 ,获得积分10
15秒前
猜不猜不完成签到 ,获得积分10
16秒前
16秒前
聪慧的迎夏完成签到,获得积分10
16秒前
哈哈哈哈完成签到,获得积分10
17秒前
秋风的应助被仁爱的沁采纳,获得110
18秒前
遮天完成签到,获得积分10
19秒前
生物科研小白完成签到 ,获得积分10
19秒前
机灵瑛完成签到,获得积分10
19秒前
茴香发布了新的文献求助10
20秒前
franklylyly完成签到,获得积分10
21秒前
KOW完成签到 ,获得积分10
21秒前
Luuuuu完成签到 ,获得积分10
21秒前
行走完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185571
求助须知:如何正确求助?哪些是违规求助? 9574336
关于积分的说明 21835187
捐赠科研通 7783367
什么是DOI,文献DOI怎么找? 3434606
关于科研通互助平台的介绍 2558985
邀请新用户注册赠送积分活动 2481374